While the Buy rating reaffirms confidence in EyePoint Pharmaceuticals, the reduction in price target could suggest a more conservative outlook on the company's future performance. This may lead to mixed reactions in the short term, as the maintained Buy rating could be seen as positive, but the lowered price target might raise concerns among investors.